TriangleNCT01721057 · OUTCOME
Mean Duration of Morning Joint Stiffness(MJS) in the Prior 7 Days as Collected in Electronic Daily Diaries
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- minutes
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Week 12
What was measured
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes into daily electronic diaries. If MJS duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit is calculated. A decrease in duration of MJS indicated an improvement in the participant's condition.
Analysis population: mITT population: all randomized participants who received at least 1 dose of the study drug and had at least 4 entries within any post-baseline 7-day window are included in the analysis.
Groups in this outcome
Placebo
Placebo administered orally once daily through Week 24. Participants continued disease-modifying antirheumatic drug (cDMARD) therapy throughout study.
Baricitinib 2 mg
Baricitinib 2 mg administered orally once daily through Week 24. Participants continued to take background cDMARD therapy throughout study.
Baricitinib 4 mg
Baricitinib 4 mg administered orally once daily through Week 24. Participants continued to take background cDMARD therapy throughout study.
| Group | Source count |
|---|---|
| Placebo | 221 |
| Baricitinib 2 mg | 223 |
| Baricitinib 4 mg | 222 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Placebo | 60.0 | Not reported | 50.7 | 76.7 | Not reported |
| Baricitinib 2 mg | 44.4 | Not reported | 30.0 | 60.0 | Not reported |
| Baricitinib 4 mg | 34.6 | Not reported | 23.7 | 51.4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 50.7
- upper Limit
- 76.7
- value
- 60.0
- group Id
- OG001
- lower Limit
- 30.0
- upper Limit
- 60.0
- value
- 44.4
- group Id
- OG002
- lower Limit
- 23.7
- upper Limit
- 51.4
- value
- 34.6
- denoms
- counts
- group Id
- OG000
- value
- 221
- group Id
- OG001
- value
- 223
- group Id
- OG002
- value
- 222
- units
- Participants
- description
- Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes into daily electronic diaries. If MJS duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit is calculated. A decrease in duration of MJS indicated an improvement in the participant's condition.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Placebo administered orally once daily through Week 24. Participants continued disease-modifying antirheumatic drug (cDMARD) therapy throughout study.
- id
- OG000
- title
- Placebo
- description
- Baricitinib 2 mg administered orally once daily through Week 24. Participants continued to take background cDMARD therapy throughout study.
- id
- OG001
- title
- Baricitinib 2 mg
- description
- Baricitinib 4 mg administered orally once daily through Week 24. Participants continued to take background cDMARD therapy throughout study.
- id
- OG002
- title
- Baricitinib 4 mg
- param Type
- MEDIAN
- population Description
- mITT population: all randomized participants who received at least 1 dose of the study drug and had at least 4 entries within any post-baseline 7-day window are included in the analysis.
- reporting Status
- POSTED
- time Frame
- Week 12
- title
- Mean Duration of Morning Joint Stiffness(MJS) in the Prior 7 Days as Collected in Electronic Daily Diaries
- type
- SECONDARY
- unit Of Measure
- minutes
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice